The use of European Organization of Research and Treatment of Cancer Risk Tables to predict the prognosis of patients with T1 non-muscle-invasive bladder cancer
10.3969/j.issn.1000-8179.2016.15.578
- VernacularTitle:EORTC危险评分系统对T1期非肌层浸润性膀胱癌患者的预后评价
- Author:
Rui LIN
;
Jun DU
;
Yanhui ZHANG
;
Qinanqian CHEN
;
Honglei LI
;
Xin YAO
- Publication Type:Journal Article
- Keywords:
T1;
non-muscle-invasive bladder cancer;
recurrence;
progression;
independent prognostic factors
- From:
Chinese Journal of Clinical Oncology
2016;43(15):655-658
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To assess the accuracy of the European Organization of Research and Treatment of Cancer (EORTC) Risk Tables in predicting the prognosis of patients with T1 non-muscle-invasive bladder cancer (NMIBC) treated in the Tianjin Medical University Can-cer Institute and Hospital (TMUCIH). The prognostic factors of T1 NMIBC are also explored, and a new risk scoring model suitable for T1 NMIBC is determined. Methods:We retrospectively reviewed the clinicopathologic characteristics of 108 patients with T1 NMIBC who underwent transurethral resections in TMUCIH from January 2011 to June 2013. We scored patients based on the number of ad-verse factors. Afterwards, divided them into different risk groups by the limits determined using receiver operating characteristic curve (ROC) analysis, and created a new risk scoring model. Results:In a group of 108 patients, 90 (83%) were male and 18 were female (17%). The median age was 65 years old (ranging from 24 to 88). Furthermore, 21 patients (19.4%) had a recurrence and 11 cases (10.2%) progressed to muscle-invasive disease. Conclusion:The EORTC cannot accurately predict the recurrence and progressive rate of T1 NMIBC. The most important prognostic factors for recurrence were tumor size and prior recurrence rate. Tumor grade and prior recurrence rate are independent prognostic factors for tumor progression. The new risk scoring model is more accurate in predicting the recurrence risk and progression of T1 NMIBC.
